This work consists on a group of sceintific and technological activities to fullfill the government´s assignment of having all HIV/AIDS infected cubans recieve High Efficiency Antiretriviral Therapy (TARVAE) with the same developed countries quality. It has two great components: first, establishing bioequivalence of stavudine, zidovudine and lamivudine generics and compare it to the international market leading product; it includes demostrating bioavailability, pharmacokinetics and the rest of pharmacologic stuides; and also drug equivalence to leading product, and second: defining the impact of using nationally produced generic antiretrivirals on AIDS sufferers and seropositive persons. Four therapeutic models were developed to correlate the drugs´ efficiency. All results were highly satisfactory, obtaining indicators never reached before in Cuba. Free symtom sick persons were reincorporated to their medium, often associated to labor insertion. Economically speaking, a substantial reduction of medical care costs could be seeen, as well as the chance of exporting these products. In the current year, WHO published on this work´s authors. Likewise, some other national and international publications were made in journals of impact , as well as presentations in national and international events.